BTO-1
|
2物価
選択条件:
ブランド
- Sigma-Aldrich Japan
パッケージ
- 5mg
- 25mg
- 生産者Sigma-Aldrich Japan
- 製品番号B6311
- 製品説明 ≥98% (HPLC), solid
- 英語製品説明BTO-1 ≥98% (HPLC), solid
- 包装単位5mg
- 価格¥23200
- 更新しました2024-03-01
- 購入
- 生産者Sigma-Aldrich Japan
- 製品番号B6311
- 製品説明 ≥98% (HPLC), solid
- 英語製品説明BTO-1 ≥98% (HPLC), solid
- 包装単位25mg
- 価格¥112000
- 更新しました2024-03-01
- 購入
| 生産者 | 製品番号 | 製品説明 | 包装単位 | 価格 | 更新時間 | 購入 |
|---|---|---|---|---|---|---|
| Sigma-Aldrich Japan | B6311 | ≥98% (HPLC), solid BTO-1 ≥98% (HPLC), solid |
5mg | ¥23200 | 2024-03-01 | 購入 |
| Sigma-Aldrich Japan | B6311 | ≥98% (HPLC), solid BTO-1 ≥98% (HPLC), solid |
25mg | ¥112000 | 2024-03-01 | 購入 |
プロパティ
沸点 :553.0±60.0 °C(Predicted)
比重(密度) :1.89±0.1 g/cm3(Predicted)
貯蔵温度 :2-8°C
溶解性 :H2O: <2ML/mL
酸解離定数(Pka) :14.67±0.30(Predicted)
外見 :solid
色 :tan
水溶解度 :H2O: <2mL/mL
DMSO: ≥5mg/mL InChI :1S/C9H4N4O4S/c10-3-4-1-5-7(6(2-4)13(16)17)18-9(8(11)14)12(5)15/h1-2H,(H2,11,14)
InChIKey :FKRBAXZAJBBIAJ-UHFFFAOYSA-N
SMILES :NC(=O)c1sc2c(cc(cc2[n+]1[O-])C#N)[N+]([O-])=O
比重(密度) :1.89±0.1 g/cm3(Predicted)
貯蔵温度 :2-8°C
溶解性 :H2O: <2ML/mL
酸解離定数(Pka) :14.67±0.30(Predicted)
外見 :solid
色 :tan
水溶解度 :H2O: <2mL/mL
DMSO: ≥5mg/mL InChI :1S/C9H4N4O4S/c10-3-4-1-5-7(6(2-4)13(16)17)18-9(8(11)14)12(5)15/h1-2H,(H2,11,14)
InChIKey :FKRBAXZAJBBIAJ-UHFFFAOYSA-N
SMILES :NC(=O)c1sc2c(cc(cc2[n+]1[O-])C#N)[N+]([O-])=O
安全情報
| 絵表示(GHS): |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注意喚起語: | Warning | |||||||||||||||||||||||||||||||||||||||||||||||||
| 危険有害性情報: |
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| 注意書き: |
|
説明
BTO-1 is a cell-permeable benzothiazolo-N-oxide compound that targets the ATP-binding pocket of polo-like kinase and is shown to inhibit Plk1 kinase activity in cell-free kinase assays (IC50 = 8.0 μM) and suppress the phosphorylation of cellular Plk1 substrate Cdc25C in rat kangaroo kidney-derived PTK cells (75% inhibition at 6.3 μM). BTO-1 treatment of cultured cells results in mitosis defects consistent with loss-of-Plk1 phenotypes seen in Plk1 RNAi-treated U20S cells, including the appearance of monopolar spindles and the reduction of γ-tubulin at the centrosomes. Plk1 inhibition by BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring.関連商品価格
- 7-Nitro-5-(trifluoromethyl)-2-Benzothiazolecarboxamide 3-oxide
¥52000-199000 - BTO-1
¥23200-112000



